Trials / Completed
CompletedNCT04941768
An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION)
Real-world Evaluation of Efficacy and Safety With Avelumab (BAVENCIO®) + Axitinib (INLYTA®) in Patients With aRCC in Multiple EU Countries (AVION)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 105 (actual)
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to expand knowledge on the effectiveness of Avelumab intravenous infusion in combination with Axitinib as the first-line therapy in participants with advanced renal-cell carcinoma (aRCC) in addition to the safety and tolerability under routine conditions of daily clinical practice.
Conditions
Timeline
- Start date
- 2021-08-09
- Primary completion
- 2024-08-08
- Completion
- 2025-04-30
- First posted
- 2021-06-28
- Last updated
- 2025-11-28
- Results posted
- 2025-11-28
Locations
61 sites across 4 countries: Belgium, Germany, Greece, Russia
Source: ClinicalTrials.gov record NCT04941768. Inclusion in this directory is not an endorsement.